The biotech and healthcare sectors are navigating volatile regulatory and market environments. FDA leadership changed with Vinay Prasad's departure amid controversies. NeoGenomics faced stock downgrades and guidance cuts reflecting funding uncertainties and market competition. Tariffs on pharmaceutical imports under a new US-EU trade deal pose financial considerations, though analysts expect a manageable impact. Industry veteran Kennedy’s anticipated overhaul of preventive health panels raises stakeholder concerns about access to essential screenings and coverage. Meanwhile, health tech continues to attract investment despite broader fundraising downturns in healthcare.